SYROS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.04 USD | -1.18% |
|
+11.01% | -35.30% |
| Apr. 09 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
| Apr. 09 | Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 293.3 | 608.9 | 201.9 | 72.61 | 202.6 | 134.7 | - | - |
| Enterprise Value (EV) 1 | 293.3 | 608.9 | 111.8 | 72.61 | 202.6 | 134.7 | 134.7 | 134.7 |
| P/E ratio | -3.68 x | -5.96 x | -2.36 x | -0.48 x | -1.34 x | -1.37 x | -1.51 x | -3.38 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 148 x | 40.3 x | 8.6 x | 4.88 x | 20.4 x | 48.1 x | 4.2 x | 0.89 x |
| EV / Revenue | 148 x | 40.3 x | 8.6 x | 4.88 x | 20.4 x | 48.1 x | 4.2 x | 0.89 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | -10,031,912 x | -2,003,747 x | - | - | - | - | - |
| FCF Yield | - | -0% | -0% | - | - | - | - | - |
| Price to Book | - | 6.74 x | 2.37 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 4,244 | 5,612 | 6,195 | 20,226 | 26,007 | 26,728 | - | - |
| Reference price 2 | 69.10 | 108.5 | 32.60 | 3.590 | 7.790 | 5.040 | 5.040 | 5.040 |
| Announcement Date | 3/5/20 | 3/4/21 | 3/15/22 | 3/2/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.982 | 15.09 | 23.49 | 14.88 | 9.936 | 2.8 | 32.08 | 151.2 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -77.74 | -82.3 | -99.42 | -135.9 | -129 | -119.1 | -110.2 | -45.2 |
| Operating Margin | -3,922.35% | -545.27% | -423.28% | -913.12% | -1,298.19% | -4,252.68% | -343.52% | -29.9% |
| Earnings before Tax (EBT) 1 | -75.44 | -84.04 | -86.56 | -94.65 | -164.6 | -128 | -120.1 | -54.2 |
| Net income 1 | -75.44 | -84.04 | -86.56 | -94.65 | -164.6 | -124.9 | -120.1 | -54.2 |
| Net margin | -3,806.16% | -556.8% | -368.52% | -636.12% | -1,656.34% | -4,461.25% | -374.34% | -35.85% |
| EPS 2 | -18.80 | -18.20 | -13.80 | -7.490 | -5.810 | -3.688 | -3.344 | -1.493 |
| Free Cash Flow | - | -60.7 | -100.8 | - | - | - | - | - |
| FCF margin | - | -402.17% | -429.09% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/4/21 | 3/15/22 | 3/2/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.697 | 7.802 | 5.467 | 6.276 | 3.891 | -0.754 | 2.954 | 2.833 | 3.762 | 0.386 | 0.72 | 0.72 | 0.72 | 0.72 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -26.91 | -25.42 | -26.65 | -33.77 | -39.45 | -36 | -33.21 | -34 | -34.64 | -27.14 | -27.78 | -29.12 | -29.32 | -32.85 | -36 |
| Operating Margin | -472.37% | -325.85% | -487.53% | -538.07% | -1,013.98% | 4,774.14% | -1,124.31% | -1,200.14% | -920.68% | -7,031.09% | -3,857.64% | -4,045.14% | -4,072.92% | -4,562.5% | - |
| Earnings before Tax (EBT) 1 | -26.03 | -23.81 | -25.15 | -34.48 | -30.25 | -4.773 | -23.79 | -36.26 | -40.14 | -64.38 | -29.76 | -31.29 | -31.65 | -35.29 | -36.48 |
| Net income 1 | -26.03 | -23.81 | -25.15 | -34.48 | -30.25 | -4.773 | -23.79 | -36.26 | -40.14 | -64.38 | -29.76 | -31.29 | -31.65 | -35.29 | -36.48 |
| Net margin | -456.85% | -305.22% | -459.96% | -549.41% | -777.51% | 633.02% | -805.31% | -1,279.84% | -1,067.07% | -16,679.79% | -4,133.68% | -4,346.35% | -4,395.83% | -4,901.04% | - |
| EPS 2 | -4.100 | -3.800 | -4.000 | -5.400 | -3.210 | -0.1700 | -0.8500 | -1.300 | -1.430 | -2.220 | -0.8700 | -0.9080 | -0.9100 | -1.000 | -0.9200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/5/21 | 3/15/22 | 5/16/22 | 8/9/22 | 11/14/22 | 3/2/23 | 5/10/23 | 8/8/23 | 11/14/23 | 3/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | 90.1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -60.7 | -101 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -99% | -102% | -88.9% | - | - | - | 105% |
| ROA (Net income/ Total Assets) | - | -46.3% | -47.3% | -44.3% | - | -252% | -45.1% | - |
| Assets 1 | - | 181.6 | 182.9 | 213.7 | - | 49.53 | 266.3 | - |
| Book Value Per Share | - | 16.10 | 13.70 | - | - | - | - | - |
| Cash Flow per Share 2 | - | -12.50 | -15.20 | -9.740 | - | -3.010 | -0.5500 | 1.980 |
| Capex | - | 3.34 | 1.25 | - | - | - | - | - |
| Capex / Sales | - | 22.1% | 5.3% | - | - | - | - | - |
| Announcement Date | 3/5/20 | 3/4/21 | 3/15/22 | 3/2/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.04
USD
Average target price
19.25
USD
Spread / Average Target
+281.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.30% | 135M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SYRS Stock
- Financials Syros Pharmaceuticals, Inc.
